Table 1.
Participant characteristics by sector and overall
| Characteristics | CTU/public (N=46) |
Industry (N=18) |
Overall (N=64) |
||||
| n/N | % | n/N | % | n/N | % | ||
| Typical trial size | 1–10 | 0/46 | 0.0 | 1/18 | 5.6 | 1/64 | 1.6 |
| 11–50 | 0/46 | 0.0 | 1/18 | 5.6 | 1/64 | 1.6 | |
| 51–100 | 6/46 | 13.0 | 4/18 | 22.2 | 10/64 | 15.6 | |
| 101–500 | 28/46 | 60.9 | 9/18 | 50.0 | 37/64 | 57.8 | |
| >500 | 12/46 | 26.1 | 3/18 | 16.7 | 15/64 | 23.4 | |
| Work setting | Academic institution | 38/46 | 82.6 | 0/18 | 0.0 | 38/64 | 59.4 |
| CRO | 1/46 | 2.2 | 7/18 | 38.9 | 8/64 | 12.5 | |
| NHS trust | 5/46 | 10.9 | 0/18 | 0.0 | 5/64 | 7.8 | |
| Pharmaceutical | 0/46 | 0.0 | 9/18 | 50.0 | 9/64 | 14.1 | |
| Other | 2/46 | 4.3 | 2/18 | 11.1 | 4/64 | 6.3 | |
| Speciality* | No | 23/46 | 50.0 | 7/18 | 38.9 | 30/64 | 46.9 |
| Yes | 23/46 | 50.0 | 11/18 | 61.1 | 34/64 | 53.1 | |
| Typical trial phase | Phase I/dose finding | 1/46 | 2.2 | 4/18 | 22.2 | 5/64 | 7.8 |
| Phase II/III | 38/46 | 82.6 | 12/18 | 66.7 | 50/64 | 78.1 | |
| Phase IV | 7/46 | 15.2 | 2/18 | 11.1 | 9/64 | 14.1 | |
| Years of experience | Mean (SD) | 12.0 | (7.2) | 14.7 | (10.7) | 12.8 | (8.3) |
| Median (min, max) | 12.0 | (1, 30) | 15.5 | (1, 35) | 11.5 | (1, 35) | |
*Participants were asked if there was a clinical area they predominantly worked on.
CRO, clinical research organisation; CTU, clinical trial unit; max, maximum; min, minimum; SD, standard deviation.